1. Home
  2. TMCI vs VCRE Comparison

TMCI vs VCRE Comparison

Compare TMCI & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$4.46

Market Cap

292.0M

Sector

Health Care

ML Signal

HOLD

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

N/A

Current Price

$9.19

Market Cap

316.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TMCI
VCRE
Founded
2014
N/A
Country
United States
Sweden
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
292.0M
316.4M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
TMCI
VCRE
Price
$4.46
$9.19
Analyst Decision
Hold
Analyst Count
6
0
Target Price
★ $4.77
N/A
AVG Volume (30 Days)
★ 202.8K
17.0K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $212,690,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.59
N/A
52 Week Low
$1.17
$9.50
52 Week High
$7.08
$13.15

Technical Indicators

Market Signals
Indicator
TMCI
VCRE
Relative Strength Index (RSI) 45.93 30.06
Support Level $4.31 N/A
Resistance Level $4.47 $13.00
Average True Range (ATR) 0.20 0.63
MACD -0.02 -0.12
Stochastic Oscillator 31.33 22.92

Price Performance

Historical Comparison
TMCI
VCRE

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: